ALSO NOTED: Forest sues generics over Namenda; Omrix gets new indication for Evicel;

> Forest Labs and Merck KGaA are suing several generics makers--including Barr, Cobalt, Lupin, Orchid, Teva, and Wockhardt--for infringing patents on the Namenda treatment for Alzheimer's. Report

> Omrix Biopharmaceuticals got the FDA's blessing for a new use of its Evicel sealant product. Report

> FDA approvals may be down in the doldrums, but approvable letters flew out of the agency in 2007--at a rate 40 percent higher than in 2006. Report

> The FDA is postponing its review of an anti-constipation drug candidate developed by Progenics and Wyeth. Report

> UK investors are turning up their noses at biotech these days, but a few companies are poised for a comeback. Report

> Is Pfizer a good buy now that shares are going for just 10 times forecast earnings? Smart Money does the analysis. Report

> UK pharmacies are launching an online registration system to help curb online sales of fake and dangerous medicines. Report

> Noven Pharmaceuticals got an FDA warning of potential manufacturing deficiencies at its Miami plant; the problems related to Noven's Daytrana transdermal product. Report

And Finally... Next time you fight with your spouse over getting directions, you'll know to blame your brain. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.